Tracer library / [177Lu]Lu-AMTG
[177Lu]Lu-AMTG
Also written as [Lu-177]Lu-AMTG; Lu-177-AMTG
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 3
What it is
- Compound class
- GRPR-targeting radiolabeled peptide (α-Me-Trp8-RM2 antagonist analog, DOTA-conjugated)
- Target / mechanism
- Gastrin-releasing peptide receptor (GRPR) antagonist PMID 38124121
- Clinical application
- GRPR-targeted radiopharmaceutical therapy of GRPR-expressing malignancies, including metastatic castration-resistant prostate cancer PMID 40306971
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | none | quantitative | >95% | AMTG (α-Me-Trp8]RM2) | 40890559 2025 EJNMMI Res |
| Manual synthesis | — | none | quantitative | >98% | AMTG (α-Me-l-Trp8-RM2) | 35027371 2022 J Nucl Med 177Lu labeling of all compounds was performed manually - 177Lu labeling of all compounds was performed manually, each resulting in quantitative radiochemical yields |
| Manual synthesis n/a | — | — | — | — | AMTG | 42429818 2026 Eur J Nucl Med Mol Imaging 161Tb- and 177Lu-Labeling was completed at 90 °C within 10 min (1.0 M sodium acetate buffer, pH = 5.5, molar activity of ~ 50 MBq/nmol) |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- First-in-Human Serum Stability Studies of [177Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy.2025 · J Nucl Med · Clinical study
Need this precursor?We can point you to suppliers for [177Lu]Lu-AMTG, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40890559: '[α-Me-Trp8]RM2 (= AMTG)'. Stage set/updated at stage 23 from PMID 40306971: 'First-in-Human Serum Stability Studies of [177Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy.'. | Stage 30 (2026-09-18): Stage was 'first-in-human'; normalised to 'Clinical research', original wording kept here.